Tirzepatide

Typical use cases

Dosing guidelines

Titration

Commonly reported protocols escalate in 2.5 mg increments no sooner than every 4 weeks: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly. The 2.5, 7.5, and 12.5 mg steps are generally described as transitional titration steps rather than maintenance levels; slower escalation is frequently reported to improve gastrointestinal tolerability.

Reconstitution

N/A for commercial single-dose pens/vials, which are supplied as a ready-to-use sterile solution. Lyophilized research powder requires reconstitution with bacteriostatic or sterile water; the resulting concentration depends on powder mass and diluent volume added.

Injection sites

Subcutaneous injection, commonly into the abdomen, thigh, or upper arm; sites are typically rotated

Storage & handling

Refrigerate at 2-8°C (36-46°F); protect from light and do not freeze. Commercial product may be kept at room temperature up to 30°C (86°F) for up to a total of 21 days before use, then discarded. Reconstituted research solution is kept refrigerated.

Side effects

• Nausea Mild · Common
• Diarrhea Mild · Common
• Vomiting Moderate · Common
• Constipation / decreased appetite Mild · Common
• Dehydration with potential acute kidney injury (from severe GI effects) Severe · Uncommon
• Acute pancreatitis Severe · Rare

Research summary

Tirzepatide is a 39-amino-acid synthetic peptide based on the native GIP sequence, conjugated to a C20 fatty-diacid that binds albumin to extend its half-life to roughly 5 days, enabling once-weekly subcutaneous dosing. It is a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors; pharmacology studies (e.g., the JCI Insight characterization, PMC7526454) describe it as an imbalanced, biased dual agonist showing greater engagement of the GIP receptor than the GLP-1 receptor, with reported GLP-1R affinity weaker than native GLP-1 and signaling at GLP-1R biased toward cAMP generation over beta-arrestin recruitment. Human evidence is robust and includes the SURPASS program in type 2 diabetes (large HbA1c and weight reductions versus comparators including dulaglutide and basal insulin) and the SURMOUNT program in obesity. In the randomized, double-blind, placebo-controlled SURMOUNT-1 trial (2,539 adults, published in NEJM), participants achieved mean weight reductions of approximately 16.0%, 21.4%, and 22.5% at 5/10/15 mg respectively versus 2.4% with placebo over 72 weeks. Reported benefits in trials extended to blood pressure, lipids, and glycemic markers, with gastrointestinal adverse events being the most common and generally mild-to-moderate during dose escalation. Key limitations include a rodent thyroid C-cell tumor (medullary thyroid carcinoma) boxed warning whose human relevance is unestablished, frequent GI tolerability issues, commonly reported weight regain after discontinuation, and more limited very-long-term outcome data relative to older agents. As with any incretin agent, individual response and tolerability vary, and this summary is educational rather than clinical guidance.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC7843845/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC7526454/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10962491/
• https://www.prnewswire.com/news-releases/lillys-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-301561327.html
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0

Related compounds